Anemia Clinical Trial
Official title:
The Immunomodulatory Effects of Phlebotomy
Although phlebotomy is routinely performed in blood donors, and seemingly does not have significant health risks, it is highly relevant to know what the effect of phlebotomy is on immunity. Alterations in immunity due to phlebotomy could have beneficial effects, like the suppression of the low grade inflammatory process that contributes to atherosclerosis, but in theory could also contribute to a suppressed innate immune response that could increase the risk of infection. This is not only relevant for blood donors, but also for patients suffering from blood loss and for daily clinical practice in which blood is routinely drawn of patients for laboratory determinations.
The loss of blood by haemorrhage or routine phlebotomy as performed during blood donation by
healthy volunteers, has large effects on systemic iron homeostasis. The relative shortage of
erythrocytes after blood loss is compensated for by increasing the production of new red
cells by the bone marrow. As iron is needed for effective haemoglobin synthesis, the
transport of iron to the bone marrow needs to be increased. This is accomplished by the
suppression of hepcidin production in the liver. Hepcidin is the central regulator of iron
homeostasis. It can regulate serum iron levels effectively by downregulating iron channel
ferroportin on iron exporting cells. Hepcidin production is increased in response to
inflammation en high systemic iron content, and is suppressed by increased erythrocyte
production, hypoxia, anemia, and low systemic iron content. Therefore, blood loss leads to
hepcidin suppression, increased release of iron into the circulation and decrease of iron
stores.
Alterations in iron metabolism can have immunomodulatory effects. The intra cellular iron
content in macropahges and monocytes, has shown pro-inflammatory effects in several
investigations. Hepcidin is reported to have pro-inflammatory effects in some reports, and
anti-inflammatory effects in others.
Although phlebotomy is routinely performed in blood donors, and seemingly does not have
significant health risks, it is highly relevant to know what the effect of phlebotomy is on
immunity. Alterations in immunity due to phlebotomy could have beneficial effects, like the
suppression of the low grade inflammatory process that contributes to atherosclerosis, but
in theory could also contribute to a suppressed innate immune response that could increase
the risk of infection. This is not only relevant for blood donors, but also for patients
suffering from blood loss and for daily clinical practice in which blood is routinely drawn
of patients for laboratory determinations.
Objective: To assess the ex vivo cytokine production of whole blood during 28 days after
phlebotomy (routine withdrawal of 500 ml of blood).
Study design: Intervention study in 10 healthy male volunteers.
Study population: 10 healthy male volunteers in the age of 18-35 years.
Intervention (if applicable): Withdrawal of 500 mL of blood at the blood bank (Sanquin,
Nijmegen, The Netherlands).
Main study parameters/endpoints:
- Ex vivo cytokine production of whole blood, drawn on day -1, 0, 1, 3, 5, 7, 14, 21, 28.
- Hemoglobin, hematocrit, white blood cell count and differential
- Hepcidin
- Iron parameters (serum iron, transferrin saturation, ferritin)
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness:
10 healthy young male volunteers will be included in this study. The study consists of 10
visits: 1 screening visit and 9 follow-up visits. The screening visit consists of a medical
history questionnaire. On day 0, Phlebotomy of 500 ml of blood will be performed at the
Sanquin blood bank, Nijmegen according to normal procedures. Risks associated with
phlebotomy are, discomfort during puncture, light-headedness, orthostatic hypotension,
vasovagale response, and hematoma at the puncture site.
On day -1, 0, 1, 3, 5, 7, 14, 21 and 28, a volume of 7 mL of blood will be drawn by
venapuncture. Associated risks are discomfort during puncture , vasovagale response, and
hematoma at the puncture site.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
| Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
| Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
| Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
| Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
| Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
| Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
| Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
| Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
| Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
| Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
| Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
| Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 | |
| Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A |